(Q35879839)

10 August 2017

Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2. (English)

1 reference

10 August 2017

1 reference

metastatic breast cancer

1 reference

E Brain

1

1 reference

10 August 2017

N Isambert

2

1 reference

10 August 2017

F Dalenc

3

1 reference

10 August 2017

V Diéras

4

1 reference

10 August 2017

J Bonneterre

5

1 reference

10 August 2017

K Rezai

6

1 reference

10 August 2017

M Jimenez

7

1 reference

10 August 2017

F Mefti-Lacheraf

8

1 reference

10 August 2017

E Cottura

9

1 reference

10 August 2017

P Tresca

10

1 reference

10 August 2017

L Vanlemmens

11

1 reference

10 August 2017

C Mahier-Aït Oukhatar

12

1 reference

10 August 2017

F Lokiec

13

1 reference

10 August 2017

P Fumoleau

14

1 reference

10 August 2017

language of work or name

English

0 references

publication date

12 January 2012

1 reference

British Journal of Cancer

10 August 2017

1 reference

10 August 2017

106

1 reference

10 August 2017

4

1 reference

10 August 2017

673-677

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.2011.591

10 August 2017

0 references

cites work

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322949

Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322949

Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322949

Her2-positive breast cancer: herceptin and beyond.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322949

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322949

Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322949

A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322949

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322949

Lapatinib: current status and future directions in breast cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322949

HER2 therapy: molecular mechanisms of trastuzumab resistance.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322949

Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322949

Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322949

Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322949

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322949

Preclinical and Clinical Pharmacology of Vinca Alkaloids

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322949

Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS).

11 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.591

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.591

The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.591

New sensitive liquid chromatography method coupled with tandem mass spectrometric detection for the clinical analysis of vinorelbine and its metabolites in blood, plasma, urine and faeces

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.591

Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322949

CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes

24 September 2018

1 reference

12 December 2020

Treatment of metastatic breast cancer with vinorelbine and docetaxel

1 reference

12 December 2020

[A phase-I clinical study of a combination therapy of vinorelbine and capecitabine in patients with advanced/recurrent breast cancer]

1 reference

12 December 2020

A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.2011.591

1 reference

release_lq4bodw4ejgkfbhy2hejx76ojm

10 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lq4bodw4ejgkfbhy2hejx76ojm

24 November 2022

mapped directly with Wikidata item

1 reference

10 August 2017

PubMed publication ID

22240778

1 reference